Botulinum toxin type A for dysthyroid upper eyelid retraction

Ophthalmic Plastic and Reconstructive Surgery

Volumn 20, Issue 3, 2004, Pages 181-185

  Morgenstern, Kenneth E ^a,e   Evanchan, J ^a   Foster, J A ^a   Cahill, K V ^a   Burns, J A ^a   Holck, D E E ^b   Perry, J D ^c   Wulc, A E ^d  

^a OHIO STATE UNIVERSITY   (United States)

^b WILFORD HALL MEDICAL CENTER   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d WILLS EYE HOSPITAL   (United States)

^e NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DIPLOPIA; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; ENDOCRINE OPHTHALMOPATHY; EYELID RETRACTION; FEMALE; HUMAN; INFLAMMATION; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PTOSIS; REFLEX; TREATMENT OUTCOME; UPPER EYELID;

ADULT; AGED; AGED, 80 AND OVER; BOTULINUM TOXIN TYPE A; EYELID DISEASES; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROMUSCULAR AGENTS; PROSPECTIVE STUDIES; THYROID DISEASES; TREATMENT OUTCOME;

EID: 2542429155     PISSN: 07409303     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002341-200405000-00001     Document Type: Article

References (15)

1. Frueh BR. Graves' eye disease: orbital compliance and other physical measurements. Trans Am Ophthalmol Soc 1984;82:492-598.
2. Cockerham KP, Hidayat AA, Brown HG, et al. Clinicopathologic evaluation of the Mueller muscle in thyroid-associated orbitopathy. Ophthal Plast Reconstr Surg 2002;18:11-7.
3. Buffam FV, Rootman J. Lid retraction: its diagnosis and treatment. Int Ophthalmol Clin 1978;18:75-86.
4. Werner SC. Ocular manifestations in the thyroid. In: Ingbar S, Werner S, eds. The Thyroid. New York: Harper and Row; 1971:528.
5. Marine D. Studies on pathological physiology of exophthalmos of Graves' disease. Ann Intern Med 1938;12:443.
6. Gay AJ, Wolkstein MA. Topical guanethidine therapy for endocrine lid retraction. Arch Ophthalmol 1966;76:364-7.
7. Small RG. Enlargement of the levator palpebrae superiorus muscle fibers in Graves ophthalmopathy. Ophthalmology 1980;96:424-30.
8. Mandal A, Robinson RJ. Indications and efficacy of botulinum toxin in disorders of the gastrointestinal tract. Eur J Gastroenterol Hepatol 2001;13:603-9.
9. da Silveira EB, Rogers AI. Treatment of achalasia with botulinum A toxin. Am J Ther 2002;9:157-61.
10. Messineo A, Codrich D, Monai M, et al. The treatment of internal anal sphincter achalasia with botulinum toxin. Pediatr Surg Int 2001;17:521-3.
11. Ozkan SB, Can D, Soylev MF, et al. Chemodenervation in treatment of upper eyelid retraction. Ophthalmolgica 1997;211:387-90.
12. Uddin JM, Davies PD. Treatment of upper eyelid retraction associated with thyroid eye disease with subconjunctival botulinum toxin injection. Ophthalmology 2002;108:1183-7.
13. Ebner R. Botulinum toxin type A in upper lid retraction of Graves' ophthalmopathy. J Clin Neuroophthalmol 1993;13:258-61.
14. Biglan AW. Control of eyelid retraction associated with Graves' disease with botulinum A toxin. Ophthal Surg 1994;25:186-8.
15. Scott AB. Injection treatment of endocrine orbital myopathy. Doc Ophthalmol 1984;58:141-5.